Merck Wins Two R&D 100 Awards for Innovation in 2018

• BioReliance® Viral and Gene Therapy Assay Portfolio wins award in Analytical/Test category
• Merck’s proxy-CRISPR wins Special Recognition Market Disruptor – Products award

Darmstadt, Germany, November 27, 2018 — Merck, the vibrant science and technology company, today announced that it has won two R&D 100 Awards. The 56th annual R&D 100 Awards program, honoring the 100 most innovative and significant technologies introduced in the past year, recognized Merck for its BioReliance® Viral and Gene Therapy Assay Portfolio and proxy-CRISPR technology. Merck has received nine R&D 100 Awards in the past six years.

“We are honored to receive two R&D 100 Awards, one recognizing our continuous focus on making gene therapy more widely accessible to patients in need by developing and implementing our BioReliance® Viral and Gene Therapy assays rapidly,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science. “The second award highlights Merck as a market leader in gene editing — the result of our longstanding R&D focus on CRISPR technology. I am immensely proud of our teams, who, every day, live our purpose to solve the toughest problems in life science.”

Merck’s BioReliance® Viral and Gene Therapy Assay Portfolio won a R&D 100 Award in the Analytical/Test category. The BioReliance® Viral and Gene Therapy Assay Portfolio is a platform of assays that allows the timely release of viral and gene therapy vectors, cutting testing time nearly in half, while providing accurate and reliable results. Merck developed the assays specifically for viral gene therapy product characterization, purity, potency, safety and release testing.

Merck’s proxy-CRISPR technology won a Special Recognition Market Disruptor — Products award. Market disruptor awards are given to those that have the potential to be “game changers,” disrupting established technologies and transforming their respective industry.

Proxy-CRISPR is a new genome-editing tool for improving the performance of other newly discovered CRISPR proteins. This technology makes CRISPR more efficient, flexible and specific by opening up the DNA helix so researchers can make targeted sequence changes in previously inaccessible regions of the genome. Merck’s proxy-CRISPR provides a rapid and simple method to increase usability without the laborious need to re-engineer native CRISPR proteins.

The R&D 100 Awards are among the most prestigious innovation awards, honoring research and development pioneers.

Follow Merck on Twitter @Merckgroup, on Facebook @merckgroup and on LinkedIn.

メルクについて
Merck（メルク）はヘルスケア、ライフサイエンス、パフォーマンスマテリアルズの分野における世界有数のサイエンスとテクノロジー企業です。がんや多発性硬化症のためのバイオ医薬品を用いた治療法から、科学研究と生産に関する最先端システム、スマートフォンや液晶テレビ向けの液晶材料にいたるまで、約53,000人の従業員が人々の暮らしをより良くする技術の一層の進歩を目指しています。2017年は66カ国で153億ユーロの売上高を計上しました。

メルクは1668年に創業された世界で最も歴史の長い医薬・化学品会社で、 創業家が今でも、上場企業が率いるメルクグループの株式の過半数を所有しています。メルクの名称およびブランドのグローバルな権利は、メルクが保有しています。唯一の例外は米国とカナダで、両国ではEMDセローノ、ミリポアシグマ、EMDパフォーマンスマテリアルズとして事業を行っています。